The Motley Fool

3 FTSE 100 dividends I’d buy during the 2020 stock market crash

Image source: Getty Images

I’m very much a dividend investor these days, but I frequently caution that the presence of a big yield isn’t always sufficient to make a stock desirable.

That’s been hammered home recently as a string of companies have suspended their dividends in the wake of the coronavirus crisis. Although it’s affecting some that I hold myself, I think it’s a wise move to focus on balance sheet strength right now. But if you want the safest income you can find, what dividends should you go for?

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

FTSE 100 dividends

Just as we’re only allowed to shop for essentials, investing in companies that provide essentials can help secure more reliable dividends. Prime examples include utilities like Severn Trent (LSE: SVT).

Severn Trent’s share price has been reasonably resilient, losing 17% or so since the virus dip started. That’s not great, but it’s a lot better than the FTSE 100’s 26% fall – and the falls of 50% and more that riskier stocks have experienced.

Severn Trent’s dividend yield has never been one of the market’s biggest. But the share price fall has pushed the forecast yield up to 4.5% now. It’s certainly not guaranteed, and the firm’s income is not immune from the pandemic threat. But it’s surely a lot more reliable than income from companies offering more discretionary products and services.

Network services

National Grid (LSE:NG) is perhaps of even more central importance. And it’s also offers one of my favourite long-term income streams. With a fall of 14% in its share price, the market seems to see it as more resilient too. And, interestingly, National Grid shares are actually up over the past 12 months, by 4%, while the FTSE 100 has lost about a quarter of its value.

Again, the recent fall has made the dividend yield look a bit more attractive. National Grid has traditionally provided yields a little ahead of the general utility sector level, and right now we’re looking at forecasts for around 5.4%.

With operations in North America too, National Grid also offers a bit of international diversity. And that can’t be a bad thing in these restricted times.

Looking at Severn Trent and National Grid together, I’m reminded that more reliable dividends like these are not just for crisis times. No, they can always make a solid core for an income portfolio.

Long term

I also like the approach of seeking companies whose business models are necessarily directed to the long term. That includes AstraZeneca (LSE: AZN), with its multi-year drug development focus. GlaxoSmithKline fits the bill as well, but I’ll just look at one of the two today.

The AstraZeneca share price is yet another that appears resistant to the great sell-off, falling a very modest 11.5%. It’s also another that has actually gained over the past year, up 5%. As such, the recent dip hasn’t done a great deal to the forecast dividend yield, though it still stands at a respectable 3.5%.

AstraZeneca’s operations could well be hurt by the social distancing aspect of the current lockdown, and it might lose work in non-essential areas of the business. But I really don’t see a great threat to the dividend. The firm’s dividend is already keyed to its years-long earnings and balance-sheet expectations. And, in my view, it’s another example of the kind of long-term dividend we should be seeking.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.